Archit Organosys Limited has disclosed a substantial acquisition by promoter Suchit Kandar Pamin under SEBI regulations. The transaction, completed on December 15, 2025, involved the acquisition of equity shares through open market purchase, resulting in an increase in the promoter's shareholding percentage.

Transaction Details

The acquisition involved a small but significant transaction for regulatory disclosure purposes. The following table summarizes the key transaction parameters:

Shareholding Pattern Changes

The acquisition has resulted in a marginal increase in the promoter's stake in the company. The shareholding pattern before and after the transaction shows the following changes:

Company Capital Structure

Archit Organosys Limited maintains a stable capital structure with no changes resulting from this transaction. The company's equity share capital details are as follows:

Persons Acting in Concert

The disclosure identifies several persons acting in concert (PAC) with the acquirer, including family members who are part of the promoter group:

• Kandarp Amin
• Archana Amin
• Archit Amin
• Shimoli Amin
• Manini Amin

Regulatory Compliance

The transaction has been disclosed in compliance with Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The disclosure confirms that no encumbrances, voting rights other than shares, or convertible securities were involved in this transaction. The acquirer belongs to the promoter group, and the acquisition represents a straightforward equity share purchase through the open market mechanism.

Archit Organosys Limited has announced its financial results for the quarter and half-year ended September 30, 2025, showcasing robust growth in both revenue and profitability.

Financial Highlights

The company reported a significant increase in its net profit for the half-year period, rising to Rs 367.61 lakhs compared to Rs 202.46 lakhs in the previous year, marking an impressive growth of 81.7%. This substantial improvement in profitability underscores the company's effective cost management and operational efficiency.

Revenue from operations for the half-year also saw a notable uptick, reaching Rs 6,605.55 lakhs, up from Rs 5,214.97 lakhs in the prior year, representing a 26.7% increase. This growth in revenue indicates strong demand for the company's products and successful market penetration strategies.

For the quarter ended September 30, 2025, Archit Organosys posted a net profit of Rs 153.92 lakhs, a 51.5% increase from Rs 101.61 lakhs in the same quarter last year.

Key Financial Metrics

All financial figures in Rs lakhs, except for EPS

Operational Performance

The company's operating profit before working capital changes for the half-year stood at Rs 704.65 lakhs, indicating strong operational efficiency. The cash flow from operating activities remained positive at Rs 344.13 lakhs, reflecting healthy cash generation from core operations.

Balance Sheet Strength

As of September 30, 2025, Archit Organosys reported total assets of Rs 12,394.82 lakhs, with a strong equity base of Rs 7,278.09 lakhs. The company's financial position appears robust, with a balanced mix of equity and debt financing.

Management Commentary

The Board of Directors approved these unaudited financial results in their meeting held on November 13, 2025. While specific management comments were not provided in the available data, the significant improvement in financial performance suggests effective execution of the company's business strategies.

Segment Information

Archit Organosys operates in a single segment of Chemicals and Organics, aligning its focus on core competencies. The company does not have any subsidiary companies, simplifying its corporate structure and financial reporting.

Conclusion

Archit Organosys Limited's financial results for the first half of FY2026 demonstrate strong growth momentum, with substantial improvements in both top-line and bottom-line performance. The company's ability to significantly enhance profitability while expanding revenue indicates effective cost management and potentially improved market positioning in the chemicals and organics sector.

Investors and stakeholders may find these results encouraging, particularly the notable increase in net profit and earnings per share. However, it's important to consider these results in the context of broader market conditions and industry trends when making investment decisions.

As always, investors are advised to conduct their own research and consider their financial goals before making any investment choices.